New Zealand Pharmaceutical Manufacturing Market Size, Share & Forecast, By Product Type, Dosage Form & Manufacturing Model, 2026-2031

The New Zealand Pharmaceutical Manufacturing Market was valued at USD 915 million in 2025. The estimate represents manufacturer revenue generated from finished-dose medicines, veterinary pharmaceuticals, active ingredients, biologics, vaccines and contract manufacturing performed in New Zealand. It excludes pure import distribution, wholesale and retail activity. The market's scale is supported by 162 operating locations, 25 licensed medicine manufacturers and export demand for technically differentiated products. Human prescription medicines remain the largest product pool, while veterinary and specialty manufacturing provide disproportionate export relevance.

The market is forecast to grow at a 6.8% CAGR during 2026-2031, reaching USD 1,358 million by 2031. Growth should exceed the 5.2% historical CAGR recorded during 2020-2025 as sterile fill-finish, veterinary medicines, active ingredients and contract development gain share. Production volume is modeled to rise more slowly than value, indicating continued benefit from product complexity and pricing mix. Public medicine funding, research incentives and multi-market export programs support the outlook, while workforce scarcity and validation costs limit unconstrained expansion.

Profit pools are expected to shift toward sterile fill-finish, complex formulations, veterinary medicines, specialty active ingredients and integrated contract development. These activities combine higher technical barriers with recurring customer relationships and exportability. Commodity generics remain exposed to import competition and limited domestic scale, while integrated manufacturers can monetize formulation, analytical testing, regulatory documentation, technology transfer and commercial supply. The widening gap between value growth and volume growth indicates that mix improvement, rather than simple unit expansion, is the central economic lever through 2031.

The largest structural risk is the combination of import dependence, small domestic scale and specialist workforce scarcity. Pharmaceutical imports reached USD 1,408 million in 2024, exceeding domestic manufacturing revenue and exposing local suppliers to global pricing and supply cycles. Sector employment declined from 3,500 people in 2020 to 3,100 in 2025, making quality, engineering and validation talent harder to scale. The exit of one domestic producer previously required replacement planning for 21 funded medicines used by more than one million people.

New Zealand ranks fifth among the selected peer set by estimated 2025 manufacturer revenue, behind Singapore, South Korea, Australia and Malaysia. Its 6.8% forecast CAGR is faster than Australia and South Korea but slower than Malaysia and Singapore. The country cannot compete on scale, yet it benefits from PIC/S-aligned GMP standards, specialized animal health expertise, active ingredient capabilities and credible access to high-value export markets. These advantages support a focused manufacturing model built around quality, flexibility and niche technical depth.

Publicly funded medicine access provides the strongest baseline demand visibility. About 3.97 million New Zealanders received funded medicines, creating recurring procurement requirements across chronic, acute and specialty therapies. The medicines budget increased 4% in 2025/26 after an 11% increase in 2024/25, and 66 medicines were funded through the recent uplift. Manufacturers still need product registrations and competitive supply economics, but the breadth of reimbursement reduces demand volatility for qualified suppliers serving hospital, pharmacy and national procurement channels.